Personalis
Valuation each multiple against its own 5-year range
Vs. peers Diagnostics & Research
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Personalis (PSNL) | 1.55B | -12.30 | 7.27 | 0.00% |
| Thermo Fisher Scientific (TMO) | 248.08B | 35.31 | 4.53 | 0.27% |
| Danaher (DHR) | 155.03B | 36.12 | 2.89 | 0.69% |
| IDEXX Laboratories Inc (IDXX) | 53.28B | 45.57 | 28.50 | 0.00% |
| Agilent Technologies (A) | 48.04B | 33.61 | 6.52 | 0.59% |
| Waters (WAT) | 43.29B | 184.29 | 2.83 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 65.9% below Morningstar's fair value estimate.
Fair value
Personalis Inc is assigned a 4-star quantitative star rating, reflecting our opinion that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 34% discount to our quantitative fair value estimate of $23.67 per share; however, caution is warranted due to this estimate's very high uncertainty rating.
The company's valuation metrics increase our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its price to cash ratio of 9.0, which lies in the top 45% globally. While the liquidation value can be important for some businesses, we don't believe this is one of them. The low cash balance relative to the firm's market value could signal heavy reinvestment for growth. We believe this is a sign that shares could be undervalued.
On a different note, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's gross margin of 18.3%, a core component of profitability, lies in the bottom 30% globally. This suggests that competition is intense and profit generation could prove difficult. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.
Economic moat
This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Personalis discussion 0 comments